ASX:EVS

- Envirosuite Limited

  Archived

Oct 2, 2019 |

10 min

Actinogen closed up 466% to finish at 5.1c on $15.8 million stock traded. The company announced results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. The results demonstrate a significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.

  Archived

Sep 10, 2019 |

17 min

EVS has signed a legally binding agreement to secure a strategically funded entry into the China market that the Board sees as potentially transnational to company value.

  Archived

Mar 7, 2019 |

4 min

Envirosuite Limited (ASX:EVS) appears ready for a strong run on the back of multiple contract success with recent share price momentum.